Bruce E Sands, MD
img_Bruce E Sands
PROFESSOR | Medicine, Gastroenterology
Are you a patient?
Specialties
Gastroenterology
New topic
Dr. Sands' research as a clinical investigator focuses on extending basic pathogenetic observations in the inflammatory bowel diseases--Crohn's disease and ulcerative colitis--to translational research and clinical trials.  I have been an active investigator in clinical trials of novel agents directed at specific pathophysiologic targets in IBD in all phases of study. His earliest clinical trial work was with infliximab, a chimeric monoclonal anti-tumor necrosis factor antibody that has revolutionized the treatment of Crohn's disease. Dr. Sands was among the first to report on the efficacy of infliximab in ulcerative colitis, later borne out in large randomized controlled trials. Dr. Sands was also overall principal investigator for a large randomized controlled trial of  infliximab in fistulizing Crohn's disease, the largest such study to date.  In addistion to his work in clinical trials, Dr. Sands's research has included extensive work in observational studies in IBD, including outcomes research and epidemiologic studies.  Most recently, he is the principal investigator of OSCCAR, the Ocean State Crohn's & Colitis Area Registry, a novel, prospective, population-based inception cohort of inflammatory bowel disease based in the state of Rhode Island.  The goals of this study are to 1) develope robust predictive models for outcomes in IBD, and 2) to elucidate the role of environmental risk factors in the onset of IBD.

 

 

MD, Boston University School of Medicine

Residency, Internal Medicine, Hospital of the University of Pennsylvania

Fellowship, Gastroenterology, Massachusetts General Hospital

Certifications

American Board of Internal Medicine

2010

Chair, Immunology, Microbiology & Inflammatory Bowel Disease Section

American Gastroenterological Association

2007

Chair, Clinical Research Alliance

Crohn's & Colitis Foundation of America

Fellow

American College of Gastroenterology

Fellow

American Gastroenterological Association

Publications

Selected Publications

Longitudinal assessment of sweat-based TNF-alpha in inflammatory bowel disease using a wearable device. Robert P. Hirten, Kai Chun Lin, Jessica Whang, Sarah Shahub, Drew Helmus, Sriram Muthukumar, Bruce E. Sands, Shalini Prasad. Scientific Reports

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Silvio Danese, Remo Panaccione, Brian G. Feagan, Anita Afzali, David T. Rubin, Bruce E. Sands, Walter Reinisch, Julián Panés, Aparna Sahoo, Natalie A. Terry, Daphne Chan, Chenglong Han, Mary Ellen Frustaci, Zijiang Yang, William J. Sandborn, Tadakazu Hisamatsu, Jane M. Andrews, Geert R. D'Haens, Oleksandr Oliinyk, Leonid Bilianskyi, Jadwiga Gniady-Jastrzebska, Robert Petryka, Tomasz Arlukowicz, Piotr Gietka, Marcin Zmudzinski, Syed Mumtaz, Douglas Wolf, Katarzyna Wojcik, George Duvall, Monika Augustyn, Rafal Filip, Dino Tarabar, Alexander Tkachev, Ursula Seidler, Eran Zittan, Juris Pokrotnieks, Oksana Shchukina, Andro Machavariani, Laura Loy, Niazy Abu-farsakh, Pesegova Marina, Slobodan Sreckovic, Martin Laclav, Shu Chen Wei, Daniel Suiter, Aleksey Borsuk, Xavier Hebuterne, Carsten Buning, Adi Lahat-Zok, Wit Danilkiewicz. The Lancet Gastroenterology and Hepatology

Longitudinal monitoring of IL-6 and CRP in inflammatory bowel disease using IBD-AWARE. Robert P. Hirten, Kai Chun Lin, Jessica Whang, Sarah Shahub, Nathan K.M. Churcher, Drew Helmus, Sriram Muthukumar, Bruce Sands, Shalini Prasad. Biosensors and Bioelectronics: X

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Sands during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Protagonist Therapeutics, Inc.
  • American College of Gastroenterology
  • Janssen Scientific Affairs, LLC
  • Boehringer Ingelheim Corporation
  • Target RWE
  • Eli Lilly and Company
  • Connect Biopharm
  • Adiso Therapeutics USA
  • Synlogic
  • Alimentiv
  • AstraZeneca
  • Arena Pharmaceuticals, Inc.
  • Amgen Inc.
  • Galapagos
  • Bristol-Myers Squibb
  • HMP Global
  • Janssen Pharmaceutica NV
  • Morphic Therapeutic
  • Prometheus Biosciences
  • Immunyx Pharma
  • Surrozen
  • GossamerBio
  • Takeda (China) International Trading Co., Ltd.
  • Index Pharmaceuticals
  • Genentech, Inc.
  • WebMD
  • MJH Healthcare Holdings
  • Artizan Biosciences
  • Clinical Care Options, LLC (CCO)
  • TLL Pharmaceutical
  • Immunic
  • Progenity, Inc.
  • Celltrion Healthcare Co. Ltd.
  • Applied Molecular Transport (AMT)
  • Ferring Pharmaceuticals
  • Vindico Medical Education
  • Janssen Research & Development, LLC
  • Pfizer Australia Holdings PTY Limited
  • Cytoki Pharma
  • Fresenius Kabi
  • Integritas Communications, LLC
  • Takeda Pharmaceutical Company Limited
  • Prometheus Laboratories
  • AnaptysBio, Inc
  • Abivax
  • Focus Medical Communications
  • Imhotex
  • AbbVie Inc.
  • MRM Health NV
  • EcoR1 Capital
  • Microbiotica Limited
  • Janssen Biotech, Inc. (formerly Centocor Ortho Biotech Inc.)
  • American Gastroenterological Association (AGA)
  • Janssen-Cilag PTY, Ltd.
  • Johnson & Johnson Services, Inc.
  • Ventyx Biosciences
  • Pfizer Inc., U.S. Pharmaceuticals Group

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Ventyx Biosciences

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.